Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchAlzheon, Inc. Appoints Muneer A. Satter to Board of Directors to Guide Upcoming Commercialization Efforts.
Jan 07, 2025
FraminghamBiotechnology
Product Description
Alzheon, Inc. has announced the appointment of Muneer A. Satter to its Board of Directors as the company prepares for the commercialization of its lead product, valiltramiprosate, following a successful funding round and clinical trial.
Company Information
Company
Alzheon
Location
111 Speen Street
Framingham, Massachusetts, United States
About
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alzheon ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.